In vivo treatment of U373MG CD133+ stem cells with CRAd-Survivin-pk7 and radiation significantly inhibited tumor growth (p < 0.05), indicating that low-dose radiotherapy can enhance the activity of an oncolytic adenovirus using the radio-inducible survivin promoter [36]. Here, BIRC5 is linked to neoplasm.